We studied contractile effects in isolated electrically driven (1Hz) atrial preparations from patients undergoing cardiac bypass surgery. Adensine triphosphate (ATP) concentrationdependently (10, 30, 100 µM) rapidly decreased force of contraction (negative inotropic effect, NIE) and thereafter more slowly increased force of contraction, the maximum positive inotropic effect (PIE) at 100 µM ATP amounted to 152 % of pre-drug value (n=9), was stable and could be washed out fast and completely. The PIE did not affect time parameters of contraction (time to peak tension and time of relaxation). Moreover, a similar NIE and PIE were noted with ATP S (100 µM). In contrast 2-methyl-thio-ATP did not exert a NIE but only a PIE. In a second set of experiments, preparations were first incubated for 30 min with purinoreceptor-antagonists and in their continuous presence, 100 µM ATP was applied. However, the PIE as well as the NIE of ATP could neither be blocked with suramin (100 µM and 500 µM) nor PPADS (50 µM) nor reactive blue 2 (30, 100, 500 µM), which are known blocker for subtypes of P2-receptors, or DPCPX (1 and 10 µM), a subtype (A 1 -adenosine) P1-receptor blocker. Likewise the inhibitor of PLC activity U73122 and the inhibitor of adenylate cyclase activity SQ22563 (10 µM, each) failed to affect the NIE and the PIE of ATP. We tentatively suggest that the PIE of ATP might be mediated via P2X 4 -like receptors.
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The negative inotropic effect of ATP in the rat and in the guinea pig atrium was P1-adenosine receptor mediated because it was DPCPX-sensitive, a selective inhibitor of the A 1 -receptor subtype of the P1-receptor (25, 43) . In the rat, 2-methyl-thio-ATP only exerted a negative inotropic effect (25) while in chicken cardiomyocytes or mouse cardiomyocytes it increased contractility (44, 50) . In the ventricle of the rat, no NIE but only a small positive inotropic effect of ATP is consistently noticed (41, 54) , which is accompanied by an enhanced current through L-type-calcium channels and a resultant increase in free intracellular Ca 2+ which augments contractility (29, 54) . ATP does not sensitize the contractile proteins against Ca 2+ (21) but can alkalinize the cytosol, which may contribute to its positive inotropic effect (51) . Clinically, ATP is used to treat supraventricular arrhythmias, especially in children. As ATP is rapidly degraded to adenosine in serum, ATP blocks AV node of patients because the resultant adenosine activates A 1 -adenosine-receptors (and leads to vagal activation) and this does not involve P2-receptors (53) . Inotropic effects of ATP in the human heart (atrium or ventricle) have hitherto not been reported. In the present work, we tested the hypothesis that ATP affects contractility in the human atrium like it does in the rat atrium, i.e. a DPCPX-sensitive NIE followed by a suramin-sensitive PIE. However, while we observed a biphasic response, the antagonists that worked in the rat atrium were ineffective in the human heart, indicative of mediation by different receptors or subtypes.
Part of this work has been presented in abstract form (26) .
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Materials and Methods
Contraction experiments were performed as described previously (61, 68) . In brief, trabeculae of right atrium from patients with coronary heart disease undergoing cardiac surgery (diameter, <1mm; length, 5-8 mm) were dissected in gassed bathing solution (composition. see later) at 4°C. continuously gassed with 95% O 2 and 5% CO 2 and maintained at 37°C and pH 7.4 as described (8) . Preparations were attached to a bipolar stimulating electrode and suspended individually in 10-ml glass tissue chambers for recording isometric contractions. Force of contraction was measured with inductive force transducers connected to a chart recorder.
Time parameters of single contractions were evaluated at high chart speed. Each muscle was stretched to the length of maximal force of contraction. Trabeculae carneae were electrically stimulated at 1 Hz with rectangular pulses of 5 ms duration, the voltage was ~ 10-20 % greater than threshold. All preparations equilibrated in bathing solution until negative effect) and the maximum positive effected divided by the basal force of contraction (value before negative effect). In this way both the negative and the positive effects were expressed as percentages of the same control value (see for previous use of this calculation of the effects of ATP (25)). Data of multiple groups were compared using one way ANOVA for paired observations followed by Bonferroni´s t-test. A p value <0.05 was regarded as significant.
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Results
As depicted in the original recording in Fig. 1 , ATP concentration-dependently exerted an initial negative inotropic which rapidly (within less than 1 min) terminated and was followed by a pronounced sustained positive inotropic effect. This sequence of events was very reproducible and occurred in tissue samples from all patients investigated. The effect was discernable at 10 µM ATP, the lowest concentration used. The effect could be rapidly and completely washed out and thereafter could be elicited again. At 100 µM ATP (the highest concentration investigated) the effect was most pronounced and was stable up to 30 min (the longest time studied); this argues against a rapid desensitization of the receptor involved. 100 µM ATP was used in all subsequent experiments. The scheme in Fig. 1B depicts how we defined positive inotropic effects and negative inotropic effects of ATP (for quantification in Fig. 1C ). Using the scheme in Fig. 1B the effects of 100 µM ATP were quantified ( Fig. 1C) . Next, we quantified the time to peak tension and time of relaxation.
Using -adrenergic (by 1 µM isoproterenol) stimulation under the same experimental conditions, we noted a shortening of time of relaxation in accordance with the literature (from 123 ±15 ms to 87 ± 4 ms, n = 6, p<0.05). In contrast, ATP did not affect time parameters of contraction ( Fig. 1D ). It could be argued that the inotropic effects are mediated not by ATP per se but via its degradation products. Thus, we studied a derivative of ATP, ATP S, which is more slowly hydrolyzed than the parent compound ATP. This compound was indeed still active and induced both a negative (to 68 %) and a positive inotropic effect (to 190 %) like ATP itself ( Fig. 2A , n = 4, p<0.05). This is tentatively regarded as evidence that ATP itself acts on the preparations to exert its inotropic effect
and not a degradation product of ATP. We further noted that 100 µM 2-methyl-thio ATP exerted solely a positive inotropic under these experimental conditions (Fig. 2B) . The effects was already detectable at 10 µM 2-methyl-thio ATP. 100 µM 2-methyl-thio ATP (the highest concentration tested) increased force of contraction from 5.42 ± 0.94 to 8.52 ± 1.24 mN or by about 57 % (n=6, p<0.05), without the remotest negative inotropic effect (Fig. 2B) .
Next, we wanted to find out which subtype of receptor mediates the positive inotropic effect and/or the negative inotropic effect of ATP. To this end a number of commercially available antagonists for P1-, P2X-and/or P2Y-receptors were investigated. However, the positive inotropic effect and negative inotropic effect of ATP could neither blocked by DPCPX (Fig.   3A , a P1-receptors antagonist more specifically, an A 1 -adenosine receptor antagonist (4, 60)) nor by suramin (Fig. 3B , a P2-antagonist), nor by PPADS (Fig. 3C , a P2-antagonist), nor by reactive blue 2 (RB2, Fig. 3D here 500 µM, a P2-antagonist). Data for these antagonists are quantified in figure 4 using the calculations exemplified in figure 1B .
Apparently, the NIE of ATP is smaller in the presence of 1 µM DPCPX than in the presence of suramin, PPADS and RB2. We do not think this implies an effect of DPCPX because the NIE was still present when we used 10 µM DPCPX (data not shown). This is in contrast to data by Froldi or Mantelli and coworkers (1993, 1994) that 10 nM or 100 nM DPCPX completely blocked the NIE of ATP in rat or guinea pig atrium (25, 43) . DPCPX, suramin and PPADS alone during 30 min incubation did not alter basal force of contraction (data not shown). In human cardiac tissue the K D -value for DPCPX at A 1 -adenosine receptors was reported as 2 nM (9). Hence, the concentrations of DPCPX we used should have blocked this receptor. Indeed we have used similar concentrations of DPCPX before in human atrial tissue (60, 67) .
The PIE of ATP in the presence of 500 µM RB2 (Fig. 3D) is weak or even absent. We do not interpret this as evidence that the PIE of ATP is mediated via RB2-sensitive receptors.
In contrast, it is obvious that this is probably due to the strong innate PIE of RB2 (Fig. 3D, begin of the recording) on top of which a further positive inotropic drug is hardly effective.
We found that the maximum positive inotropic effect of isoproterenol (1 nM to 1 µM were cumulatively applied) was unchanged by RB2: the maximum positive inotropic effect of (43)) did not affect either the NIE or PIE of ATP (data not shown). RB2 at concentrations above 100 µM completely blocked human ATP degrading enzymes (46) .
Hence, it is conceivable that RB2 amplifies the effect of ATP by inhibiting its degradation.
Whatever the underlying mechanism(s) are, others also descriptively reported on a PIE of RB2 at a similar concentration (isolated guinea-pig heart preparations (64)).
To better understand the signal transduction system that mediates the inotropic effects of ATP, we tested whether its effects could be blocked by inhibitors previously used to inhibit PLC or cAMP-dependent protein kinase (PKA). We tested the involvement of these pathways because P2Y-receptors (as well as some P1-receptors) have been noted to act via these well-studied pathways (for review see 52). However, U73122 (10 µM), a PLC inhibitor, and SQ22536 (10 µM), a PKA inhibitor, did not affect the inotropic effects of ATP ( Fig. 3 E and F) . These compounds at these concentrations have been used before to study signal transduction via P2Y-receptors in the heart (mouse: 66, chicken: 50). It could be argued that under our experimental conditions these inhibitors are not effective.
Therefore, we studied the effect of UTP on force of contraction in isolated mouse left atria, which were electrically paced like our human atrial preparations in the very same set up using the same buffers. In these mouse heart preparations 100 µM UTP increased force of contraction. The effect was maximum after 10 min and amounted to 140 ± 18.6 % of predrug value (= UTP alone, p<0.05). After pre-incubation (for 30 min) of the cardiac preparations with 10 µM SQ22536 or 10 µM U73122 the PIE of 100 µM UTP in the presence of these inhibitors was blunted and amounted to 113 ± 12 % and 111 ± 17 % of pre-drug value, respectively (n = 7-11, p<0.05 vs. UTP alone).
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Discussion
The main new finding of the present work is that ATP can exert positive inotropic effects in the human cardiac atrium. It remains to be elucidated whether the same holds true for human cardiac ventricle.
The concentration of ATP within cells including cardiomyocytes (around 10 mM) is much higher than in the extracellular space (around 1-40 nM). Thus, there is a huge gradient for ATP across the membrane. ATP (usually as MgATP desensitizes to agonists (23) , which is in contrast to the observed sustained PIE towards ATP, which we report here. However, our results concur with data on P2X 4 -receptor infected chicken cardiac cells or cardiomyocytes from transgenic mice overexpressing receptors may be beneficial: crossbreeding of P2X 4 overexpressing mice with calsequestrin-overexpressing mice (a genetic model of heart failure) had a beneficial effect on cardiac function and survival (67) .
Some caveats are in order. There are heteromeric P-receptors, which are not yet fully studied with respect to agonists and antagonists (35) , which could play a role in the human atrium and a role of orphan receptors cannot be ruled out.
We can only speculate on the physiological meaning of the contractile effects of ATP. As mentioned above the intracellular concentration of ATP in cells amount is to about 10 mM (58, 62) . The concentration of ATP in the interstitium can profoundly increase during ischemia or stretch (5, 10, 39, 59) . For instance, aortic endothelial cells released ATP at a rate of 2,900 fmol/min for one million cells (49) . Another source of ATP is corelease from perivascular nerves (14) . The concentration of ATP in erythrocytes amounts to about 2 mM and 0.2 µM in plasma (e.g. 37, 58). Hence, leak of ATP from erythrocytes can rapidly lead to high ATP concentrations in the plasma.
The negative inotropic effects of ATP can only play a feedback role because they are transient over time. The positive inotropic effect of ATP is sustained over time and may therefore be physiologically important to increase contractility, should this become necessary. Hence, a conceivable scenario may be: during myocardial infarction high amounts of ATP are released from dying myocytes in order to increase force in areas of the
heart not yet damaged by cell death. Thus, ATP may subserve to maintain contractile 
